Advanced search
Publication Cover
Current Medical Research and Opinion Volume 25, 2009 - Issue 10
Submit an article Journal homepage
1,089
Views
22
CrossRef citations to date
0
Altmetric
Original Article

Sitagliptin 100 mg daily effect on DPP-4 inhibition and compound-specific glycemic improvement

M. AlbaMerck Research Laboratories, Rahway, NJ, USACorrespondence[email protected]
,
D. ShengMerck Research Laboratories, Rahway, NJ, USA
,
Y. GuanMerck Research Laboratories, Rahway, NJ, USA
,
D. Williams-HermanMerck Research Laboratories, Rahway, NJ, USA
,
P. LarsonMerck Research Laboratories, Rahway, NJ, USA
,
J.R. SachsMerck Research Laboratories, Rahway, NJ, USA
,
N. ThornberryMerck Research Laboratories, Rahway, NJ, USA
,
G. HermanMerck Research Laboratories, Rahway, NJ, USA
,
K.D. KaufmanMerck Research Laboratories, Rahway, NJ, USA
&
B.J. GoldsteinMerck Research Laboratories, Rahway, NJ, USA
 show all
Pages 2507-2514 | Accepted 27 Jul 2009, Published online: 19 Aug 2009

Citations (22)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Sreevidya Subbarayan & Mark Kipnes. (2011) Sitagliptin: a review. Expert Opinion on Pharmacotherapy 12:10, pages 1613-1622.
Read now
Bo Ahrén. (2010) Use of DPP-4 inhibitors in type 2 diabetes: focus on sitagliptin. Diabetes, Metabolic Syndrome and Obesity 3, pages 31-41.
Read now

Articles from other publishers (20)

Shreeya Tewary, Emma S. Lucas, Risa Fujihara, Peter K. Kimani, Angela Polanco, Paul J. Brighton, Joanne Muter, Katherine J. Fishwick, Maria José Minhoto Diniz Da Costa, Lauren J. Ewington, Lauren Lacey, Satoru Takeda, Jan J. Brosens & Siobhan Quenby. (2020) Impact of sitagliptin on endometrial mesenchymal stem-like progenitor cells: A randomised, double-blind placebo-controlled feasibility trial. EBioMedicine 51, pages 102597.
Crossref
Emilie S. Andersen, Asger Lund, Jonatan I. Bagger, Camilla Andreasen, Magnus F. Grøndahl, Carolyn F. Deacon, Bolette Hartmann, Jens J. Holst, Filip K. Knop & Tina Vilsbøll. (2018) Is glucagon-like peptide-1 fully protected by the dipeptidyl peptidase 4 inhibitor sitagliptin when administered to patients with type 2 diabetes?. Diabetes, Obesity and Metabolism 20:8, pages 1937-1943.
Crossref
Joel P. Berger, Ranabir SinhaRoy, Alessandro Pocai, Theresa M. Kelly, Giovanna Scapin, Ying-Duo Gao, Kelly Ann D. Pryor, Joseph K. Wu, George J. Eiermann, Shiyao S. Xu, Xiaoping Zhang, Daniel A. Tatosian, Ann E. Weber, Nancy A. Thornberry & Richard D. Carr. (2018) A comparative study of the binding properties, dipeptidyl peptidase-4 (DPP-4) inhibitory activity and glucose-lowering efficacy of the DPP-4 inhibitors alogliptin, linagliptin, saxagliptin, sitagliptin and vildagliptin in mice. Endocrinology, Diabetes & Metabolism 1:1, pages e00002.
Crossref
L. D. Carbone, P. Bůžková, H. A. Fink, J. A. Robbins, M. Bethel, C. M. Isales & W. D. Hill. (2017) Association of DPP-4 activity with BMD, body composition, and incident hip fracture: the Cardiovascular Health Study. Osteoporosis International 28:5, pages 1631-1640.
Crossref
T. Biftu & R. SinhaRoy. 2017. Comprehensive Medicinal Chemistry III. Comprehensive Medicinal Chemistry III 512 555 .
William S. Denney, Douglas S. Denham, Michael R. Riggs & Neeta B. Amin. (2016) Glycemic Effect and Safety of a Systemic, Partial Glucokinase Activator, PF-04937319, in Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin-A Randomized, Crossover, Active-Controlled Study. Clinical Pharmacology in Drug Development 5:6, pages 517-527.
Crossref
Daniel A. Tatosian, Ying Guo, Andrea K. Schaeffer, Natalia Gaibu, Serghei Popa, Aubrey Stoch, Ronald B. Langdon & Eunkyung A. Kauh. (2013) Dipeptidyl Peptidase-4 Inhibition in Patients with Type 2 Diabetes Treated with Saxagliptin, Sitagliptin, or Vildagliptin. Diabetes Therapy 4:2, pages 431-442.
Crossref
L. Zenari & A. Marangoni. (2013) What are the preferred strategies for control of glycaemic variability in patients with type 2 diabetes mellitus?. Diabetes, Obesity and Metabolism 15:s2, pages 17-25.
Crossref
Chitrabhanu BallavStephen C.L. Gough. (2013) Safety and Efficacy of Sitagliptin-Metformin in Fixed Combination for the Treatment of Type 2 Diabetes Mellitus. Clinical Medicine Insights: Endocrinology and Diabetes 6, pages CMED.S7314.
Crossref
Emma R. Parmee, Ranabir Sinharoy, Feng Xu, Jeffrey C. Givand & Lawrence A. Rosen. 2012. Case Studies in Modern Drug Discovery and Development. Case Studies in Modern Drug Discovery and Development 10 44 .
Arun K. P.Venkata Subbaiah Meda, V. S. P. Raj Kucherlapati, Anil Dubala, Deepalakshmi M.Anand VijayaKumar P. R.Elango K.Suresh B.. (2011) Pharmacokinetic drug interaction between gemfibrozil and sitagliptin in healthy Indian male volunteers. European Journal of Clinical Pharmacology 68:5, pages 709-714.
Crossref
R. D. Carr, H. L. Katzeff, C. M. Alexander, J. P. Berger, S. S. Xu & N. Thornberry. (2012) Reply to: Ahren B et al. Mechanisms of action of the dipeptidyl peptidase‐4 inhibitor vildagliptin in humans. Diabetes Obes Metab 2011; 13(9): 775–783 and Ahren B et al. Clinical evidence and mechanistic basis for vildagliptin's action when added to metformin. Diabetes Obes Metab 2011; 13(3): 193–203. Diabetes, Obesity and Metabolism 14:4, pages 383-384.
Crossref
Kathleen R. Richard, Jamie S. Shelburne & Julienne K. Kirk. (2011) Tolerability of Dipeptidyl Peptidase-4 Inhibitors: A Review. Clinical Therapeutics 33:11, pages 1609-1629.
Crossref
Angelo Avogaro. (2011) Comments on the article “Effects of vildagliptin twice daily vs. sitagliptin once daily on 24-hour acute glucose fluctuations” by Marfella et al.: (Journal of Diabetes and Its Complications 24 [2010] 79–83). Journal of Diabetes and its Complications 25:5, pages 352-353.
Crossref
Gary A. Herman, Goutam C. Mistry, Bingming Yi, Arthur J. Bergman, Amy Q. Wang, Wei Zeng, Li Chen, Karen Snyder, Jon L. Ruckle, Patrick J. Larson, Michael J. Davies, Ronald B. Langdon, Keith M. Gottesdiener & John A. Wagner. (2011) Evaluation of pharmacokinetic parameters and dipeptidyl peptidase-4 inhibition following single doses of sitagliptin in healthy, young Japanese males. British Journal of Clinical Pharmacology 71:3, pages 429-436.
Crossref
Claudine M. Chwieduk. (2011) Sitagliptin/Metformin Fixed-Dose Combination. Drugs 71:3, pages 349-361.
Crossref
Kathryn MS JohnsonKathleen Schurr. (2011) Sitagliptin: A DPP-4 Inhibitor for the Treatment of Type 2 Diabetes Mellitus. Clinical Medicine Insights: Therapeutics 3, pages CMT.S6227.
Crossref
E M Migoya, R Bergeron, J L Miller, R N K Snyder, M Tanen, D Hilliard, B Weiss, P Larson, M Gutierrez, G Jiang, F Liu, K A Pryor, J Yao, L Zhu, J J Holst, C Deacon, G Herman, N Thornberry, J Amatruda, D Williams-Herman, J A Wagner & R SinhaRoy. (2010) Dipeptidyl Peptidase-4 Inhibitors Administered in Combination With Metformin Result in an Additive Increase in the Plasma Concentration of Active GLP-1. Clinical Pharmacology & Therapeutics 88:6, pages 801-808.
Crossref
Scott D. Edmondson, Feng Xu & Joseph D. ArmstrongIIIIII. 2010. Modern Drug Synthesis. Modern Drug Synthesis 123 140 .
Sohita Dhillon. (2010) Sitagliptin. Drugs 70:4, pages 489-512.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.